Literature DB >> 15569700

Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.

Kerryn Lutchman Singh1, Melanie Davies, Ratna Chatterjee.   

Abstract

The improved long-term survival of adolescents and young women treated for cancer has resulted in an increased focus on the effects of chemotherapy on ovarian function and its preservation. These women may seek advice and treatment regarding their reproductive status, including ways of preserving their fertility and preventing a premature menopause--factors that can have a profound impact on their quality of life. This article comprehensively reviews ovarian reserve testing (ORT) in general. Special emphasis is placed on patients with cancer, including the pathophysiology of gonadal damage following chemotherapy, fertility preservation and the potential role of ORT. Baseline parameters of ovarian reserve [FSH LH, estradiol, inhibin B and anti-Mullerian hormone (AMH)] have not yet performed sufficiently well in predicting poor outcome in assisted reproduction, but biochemical markers of ovarian reserve appear to be better than chronological age. Inhibin B and AMH show potential for future use. Dynamic testing appears to show much promise, especially stimulated levels of inhibin B and estradiol. The most promising tests of ovarian reserve are the biophysical markers, where total antral follicle count was found to be most discriminatory followed by ovarian volume. Combination of biochemical, biophysical and clinical markers of ovarian reserve may also improve predictive capacity. However, there is a lack of data pertinent to ORT in cancer. As yet there is no single clinically useful test to predict ovarian reserve accurately. Patients with cancer represent a distinct cohort who have particular concerns about their future fertility and the possibility of a premature menopause, they can benefit greatly from knowledge of their functional ovarian reserve. Large, prospective, randomized, adequately controlled studies specific to different geographical areas are required in a control population of comparable reproductive age to determine the potential role of ORT in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569700     DOI: 10.1093/humupd/dmh052

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  33 in total

Review 1.  Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy--clinical approach and unsolved issues.

Authors:  Katharina Hancke; Vladimir Isachenko; Evgenia Isachenko; Jürgen M Weiss
Journal:  Support Care Cancer       Date:  2011-09-23       Impact factor: 3.603

2.  Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues.

Authors:  M Huser; L Smardova; P Janku; I Crha; J Zakova; P Stourac; J Jarkovsky; J Mayer; P Ventruba
Journal:  J Assist Reprod Genet       Date:  2015-02-28       Impact factor: 3.412

3.  Heterotopic autotransplantation of ovarian cortex in cynomolgus monkeys.

Authors:  Suguru Igarashi; Nao Suzuki; Shu Hashimoto; Seido Takae; Makoto Takenoshita; Yoshihiko Hosoi; Yoshiharu Morimoto; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2010-02-01       Impact factor: 4.174

Review 4.  Clinical guide to fertility preservation in hematopoietic cell transplant recipients.

Authors:  S Joshi; B N Savani; E J Chow; M H Gilleece; J Halter; D A Jacobsohn; J Pidala; G P Quinn; J-Y Cahn; A A Jakubowski; N R Kamani; H M Lazarus; J D Rizzo; H C Schouten; G Socie; P Stratton; M L Sorror; A B Warwick; J R Wingard; A W Loren; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

5.  Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors.

Authors:  H Irene Su; Karine Chung; Mary D Sammel; Clarisa R Gracia; Angela DeMichele
Journal:  Fertil Steril       Date:  2010-12-30       Impact factor: 7.329

6.  Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.

Authors:  Hengxi Chen; Li Xiao; Jinke Li; Lin Cui; Wei Huang
Journal:  Cochrane Database Syst Rev       Date:  2019-03-03

Review 7.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

8.  Effects of In Vitro Maturation on Histone Acetylation in Metaphase II Oocytes and Early Cleavage Embryos.

Authors:  Ning Wang; Fang Le; Qi-Tao Zhan; Li Li; Min-Yue Dong; Guo-Lian Ding; Chen-Ming Xu; Shi-Wen Jiang; He-Feng Huang; Fan Jin
Journal:  Obstet Gynecol Int       Date:  2010-06-20

9.  Oocyte-specific inactivation of Omcg1 leads to DNA damage and c-Abl/TAp63-dependent oocyte death associated with dramatic remodeling of ovarian somatic cells.

Authors:  S Vandormael-Pournin; C J Guigon; M Ishaq; N Coudouel; P Avé; M Huerre; S Magre; J Cohen-Tannoudji; M Cohen-Tannoudji
Journal:  Cell Death Differ       Date:  2014-08-29       Impact factor: 15.828

Review 10.  Breast cancer in young women and its impact on reproductive function.

Authors:  M Hickey; M Peate; C M Saunders; M Friedlander
Journal:  Hum Reprod Update       Date:  2009-01-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.